B cells critical for outcome in high grade serous ovarian carcinoma

Int J Cancer. 2024 Dec 15;155(12):2265-2276. doi: 10.1002/ijc.35149. Epub 2024 Aug 22.

Abstract

Recent work has shown evidence for the prognostic significance of tumor infiltrating B cells (B-TIL) in high grade serous ovarian carcinoma (HGSOC), the predominant histological subtype of ovarian cancer. However, it remains unknown how the favorable prognosis associated with B-TIL relates to the current standard treatments of primary debulking surgery (PDS) followed by chemotherapy or (neo-)adjuvant chemotherapy (NACT) combined with interval debulking surgery. To address this, we analyzed the prognostic impact of B-TIL in relationship to primary treatment and tumor infiltrating T cell status in a highly homogenous cohort of HGSOC patients. This analysis involved a combined approach utilizing histological data and high-dimensional flow cytometry analysis. Our findings indicate that while HGSOC tumors pre-treated with NACT are infiltrated with tumor-reactive CD8+ and CD4+ TIL subsets, only B-TIL and IgA plasma blasts confer prognostic benefit in terms of overall survival. Importantly, the prognostic value of B-TIL and IgA plasma blasts was not restricted to patients treated with NACT, but was also evident in patients treated with PDS. Together, our data point to a critical prognostic role for B-TIL in HGSOC patients independent of T cell status, suggesting that alternative treatment approaches focused on the activation of B cells should be explored for HGSOC.

Keywords: B cells; high grade serous ovarian cancer; tumor infiltrating lymphocytes.

MeSH terms

  • Aged
  • B-Lymphocytes* / immunology
  • B-Lymphocytes* / pathology
  • Chemotherapy, Adjuvant / methods
  • Cystadenocarcinoma, Serous* / immunology
  • Cystadenocarcinoma, Serous* / mortality
  • Cystadenocarcinoma, Serous* / pathology
  • Cytoreduction Surgical Procedures
  • Female
  • Humans
  • Immunoglobulin A
  • Lymphocytes, Tumor-Infiltrating* / immunology
  • Middle Aged
  • Neoadjuvant Therapy / methods
  • Neoplasm Grading
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / immunology
  • Ovarian Neoplasms* / mortality
  • Ovarian Neoplasms* / pathology
  • Ovarian Neoplasms* / therapy
  • Prognosis

Substances

  • Immunoglobulin A